AstraZeneca resumes clinical trials in UK after green signal

Meanwhile, DCGI asks Serum Institute to submit DSMB UK and India data to resume trials, after asking it to stop recruiting volunteers on Friday

While AstraZeneca resumes clinical trials in the UK, the Indian regulator has asked Serum Institute of India (SII) to suspend recruitments for phase-2 and 3 clinical trials of the Oxford-AstraZeneca vaccine candidate and has directed the firm to increase the safety monitoring of the subjects already vaccinated as part of the trial.

In a statement, the British drug major said on Saturday that following the confirmation by the Medicines Health Regulatory Authority (MHRA), clinical trials of AZD1222 have resumed in the UK. The MHRA said that it was safe to do so, the company said.

Adar Poonawallah, CEO of SII